98%
921
2 minutes
20
A key limitation of current synthetic treatments of scabies is their focus on eliminating the mites rather than addressing the body's immune response or tissue healing, potentially fostering drug resistance and prolonging recovery. Melatonin, with its anti-inflammatory, antioxidant, and antimicrobial properties, presents a potential solution. Consequently, this research seeks to assess the value of melatonin supplementation as complementary therapy in Sarcoptes scabiei mite infestation. The study included 25 male crossbreed rabbits, divided into five groups of five rabbits each: group I (a negative control); group II (a positive control); group III (infected and treated with melatonin); group IV (infected and treated with ivermectin); and group V (infected and treated with melatonin and ivermectin). Clinical and parasitological assessments were conducted from day 0 till day 28 post-treatment. Serum and tissue samples were collected at the end of day 28 post-treatment for subsequent histopathological, biochemical, and immunological analyses. Our research indicated that combining melatonin with ivermectin (group V) significantly accelerated clinical improvement compared to using ivermectin alone (group IV). Melatonin also lessened the side effects of ivermectin seen in group IV and effectively alleviated itching in group V. Skin analysis of group V revealed nearly full healing and the absence of mites, unlike group IV, which still showed inflammation and dead mites. Supporting these findings, blood tests in group V demonstrated a significant improvement in biochemical and immunological markers compared to group IV. Infestation with Sarcoptes mites disrupts the balance between oxidants and antioxidants and triggers systemic inflammation. Supplementing melatonin can help restore this balance and reduce inflammation, thereby accelerating cure in affected rabbits. Therefore, melatonin is suggested as an adjunct therapy with ivermectin, particularly in severe scabies cases, and future research should explore optimal dosages and treatment regimens.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12401764 | PMC |
http://dx.doi.org/10.1007/s00436-025-08544-7 | DOI Listing |
J Parasit Dis
September 2025
Department of Parasitology, Faculty of Veterinary Science, Bangladesh Agricultural University, Mymensingh, 2202 Bangladesh.
Anthelmintic resistance (AR) is a major problem in the profitable production of livestock. Therefore, this study evaluated AR status in cattle farms at Mymensingh Sadar using in vivo, fecal egg count reduction test (FECRT) and in vitro, egg hatch assay (EHA) techniques. For this, ten cattle farms and forty animals from individual farms with more than 200 eggs per gram (EPG) of feces were selected by employing the McMaster technique.
View Article and Find Full Text PDFParasitol Res
September 2025
Parasitology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
A key limitation of current synthetic treatments of scabies is their focus on eliminating the mites rather than addressing the body's immune response or tissue healing, potentially fostering drug resistance and prolonging recovery. Melatonin, with its anti-inflammatory, antioxidant, and antimicrobial properties, presents a potential solution. Consequently, this research seeks to assess the value of melatonin supplementation as complementary therapy in Sarcoptes scabiei mite infestation.
View Article and Find Full Text PDFInt J Infect Dis
August 2025
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Objectives: The World Health Organization recommends monitoring infection and entomological indicators to evaluate onchocerciasis elimination. We reviewed trends in Guinea-Bissau since the onset of interventions to assess current progress toward elimination.
Methods: We collated programmatic, entomological, and epidemiological data from Guinea-Bissau, including Onchocerciasis Control Programme (OCP) records, impact data, and community-directed treatment with ivermectin (CDTi) data.
Pharmaceuticals (Basel)
August 2025
Design, Isolation, and Synthesis of Bioactive Molecules Research Group, Universidad La Salle-México, Benjamín Franklin 45, Mexico City 06140, Mexico.
: Despite its initial promise as a treatment for COVID-19 due to its antiviral properties, controlled randomized trials have demonstrated a lack of clinical efficacy at standard dosages. Although its overall clinical benefits remain contentious, a recent meta-analysis suggests that ivermectin may lower the risk of mechanical ventilation in COVID-19 patients. This study aims to assess the bioequivalence of different formulations of orally administered ivermectin within a Mexican population.
View Article and Find Full Text PDFAntibiotics (Basel)
August 2025
Department of Medical Zoology, School of Medicine, Kyung Hee University, Seoul 02447, Republic of Korea.
Clonorchiasis, caused by the parasite , remains a public health concern in East Asian countries. In this study, high-throughput screening was used to analyze 320 compounds for potential inhibitory activity against . To ensure the selection of high-confidence hits, a stringent inhibition threshold of 80% was applied, leading to the identification of three active compounds: moxifloxacin, hexachlorophene, and ivermectin (IVM).
View Article and Find Full Text PDF